A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Running, not enrolling · Phase 2
Conditions studied: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
In brief
Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.
Key facts
- Study ID
- NCT06891066
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 150
- Starts
- 2025-04-14
- Expected to finish
- 2031-09-30
- Last updated by the study team
- 2025-10-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Zuckerberg San Francisco General Hospital and Trauma Center ( Site 4107) — San Francisco, California, United States
- Mills Clinical Research ( Site 4109) — West Hollywood, California, United States
- Georgetown University Medical Center ( Site 4106) — Washington D.C., District of Columbia, United States
- Orlando Immunology Center ( Site 4103) — Orlando, Florida, United States
- Triple O Research Institute ( Site 4111) — West Palm Beach, Florida, United States
- Chatham County Health Department - Chatham CARE Center ( Site 4116) — Savannah, Georgia, United States
- KC CARE Health Center ( Site 4101) — Kansas City, Missouri, United States
- Regional Center for Infectious Diseases ( Site 4115) — Greensboro, North Carolina, United States
- Central Texas Clinical Research ( Site 4100) — Austin, Texas, United States
- Prism Health North Texas, Oak Cliff Health Center ( Site 4114) — Dallas, Texas, United States
- DCOL Center for Clinical Research ( Site 4112) — Longview, Texas, United States
- Momentum Clinical Research - Darlinghurst ( Site 4260) — Darlinghurst, New South Wales, Australia
- St. Vincent's Hospital ( Site 4263) — Darlinghurst, New South Wales, Australia
- Momentum Clinical Research Fortitude Valley ( Site 4261) — Fortitude Valley, Queensland, Australia
- The Alfred Hospital ( Site 4264) — Melbourne, Victoria, Australia
- Prahran Market Clinic ( Site 4262) — Prahran, Victoria, Australia
- Ponce Medical School Foundation Inc./CAIMED Center ( Site 4301) — Ponce, Puerto Rico
- Clinical Research Puerto Rico ( Site 4300) — San Juan, Puerto Rico
- HOPE Clinical Research ( Site 4303) — San Juan, Puerto Rico
- University Hospital Basel-Infectiology ( Site 4402) — Basel, Canton of Basel-City, Switzerland
- Inselspital Bern-Inselspital Infektiologie ( Site 4403) — Bern, Canton of Bern, Switzerland
- Hôpitaux Universitaires de Genève (HUG)-Infectious Disease Department ( Site 4404) — Geneva, Canton of Geneva, Switzerland
- Ospedale Regionale di Lugano, Sede Civico-Servizio Malattie Infettive ( Site 4405) — Lugano, Canton Ticino, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.